Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | GLA | P06280 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581666 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL22076346 | 0.92 | ALDH1A1 (0.62) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL20581738 | 0.86 | ALDH1A1 (0.64) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL16806128 | 0.84 | KMT2A (0.57) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL16981577 | 0.83 | KMT2A (0.56) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL26577339 | 0.83 | ALDH1A1 (0.66) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL20581664 | 0.82 | FPR1 (0.39) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL28382736 | 0.82 | FPR1 (0.39) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL29725797 | 0.82 | KDM4E (0.62) | ALDH1A1KMT2AKDM4EGLAGAA | |
| SCHEMBL20581617 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | ALDH1A1 410/4885KMT2A 3546/4885KDM4E 4251/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | ALDH1A1 410/4885KMT2A 3546/4885KDM4E 4251/4885 |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | ALDH1A1 759/4885KMT2A 1770/4885KDM4E 2430/4885 |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | ALDH1A1 1112/4885KMT2A 1842/4885KDM4E 2438/4885 |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | ALDH1A1 759/4885KMT2A 1770/4885KDM4E 2430/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | ALDH1A1 1112/4885KMT2A 1842/4885KDM4E 2438/4885 |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | ALDH1A1 759/4885KMT2A 1770/4885KDM4E 2430/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | ALDH1A1 410/4885KMT2A 3546/4885KDM4E 4251/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | ALDH1A1 410/4885KMT2A 3546/4885KDM4E 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.